Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame with the same goal of turning the nascent CRISPR gene-editing technology into medicines.
(RTTNews) - CRISPR Therapeutics (CRSP) announced that Rodger Novak, President and Chairman of the Board of CRISPR, has elected to leave the company, effective as of September 15, 2023. As of that date ...
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Crispr Therapeutics AG (CRSP) offers a chance to buy into a pipeline of potential therapeutics, that while not yet proven, has shown early success during its clinical trials. While this company does ...
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023- -Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of ...
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results